Table 3.

Frequency of neutralizing antibodies and neutralizing activity (%) after CoronaVac in näive-PAPS compared to controls.

	After vaccine 1st dose		After vaccine 2nd dose
	Subjects with positive NAb, n (%)	Neutralizing activity (%) median (interquartile range)	Subjects with positive NAb, n (%)	Neutralizing activity (%) median (interquartile range)
PAPS, n=31	5 (16.1)a	38.1 (32–55.5)	24 (77.4)	64.3 (49.0–77.0)
Controls, n=108	38 (35.2)	43.7 (34.2–66.4)	85 (78.7)	60.9 (45.6–81.3)
p-Value (PAPS vs CG)	p =0.043	p=0.275	p=0.440	p=0.689

Results are expressed in median (interquartile range) and n (%).

Nab—neutralizing antibodies; PAPS—primary antiphospholipid syndrome; CG—control group.

Positivity for Nab defined as a neutralizing activity ≥30% (cPass sVNT Kit, GenScript, Piscataway, USA).

^ap <0.05 in comparison to controls.